Evaluation of Circulating Immune Response After Histosonics in Colorectal Cancer (ECHO-CRC)

This is a single-center, non-randomized, open-label, single-arm pilot study investigating the systemic immune response to histotripsy in patients with colorectal cancer with liver metastasis. Histotripsy is an FDA-approved, non-invasive therapeutic modality for the treatment of liver tumors, including both primary and metastatic lesions. In this study, investigators aim to evaluate the kinetics of peripheral T-cell response following histotripsy of colorectal cancer liver metastases (CRCLM). Given the well-documented immune-tolerant tumor microenvironment of liver metastases and their role in

Trial Details

NCT ID
NCT07361107
Phase
PHASE1
Sponsor
Northwell Health
Status
RECRUITING
Cancer Type
Colon Cancer Colorectal Cancer
Interventions
  • Histotripsy
Locations (sample)
  • New Hyde Park, New York, United States|40.7351,-73.68791

Key Eligibility Criteria

  • Gender: Both male and female patients will be eligible for enrollment.
  • Age at least 18 years.
  • Histologic (biopsy-proven) confirmation of metastatic microsatellite stable colorectal cancer with at least one radiographically evident hepatic me…
  • Planned treatment with standard-of-care histotripsy.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colon Cancer Colorectal Cancer Trials on Trialify →